Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 15,47 € (+131,59%). La mediana è 15,47 € (+131,59%).
| Acquista |
5 |
| Mantieni |
0 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Green Thumb Industries reports weaker Q2 but cites Virginia, Texas and tax relief as catalysts
Green Thumb reported Q2 comparable-store sales down 1.1% and gross margin falling to 45%, with EBITDA declining to $53.1 million despite revenue rising 4.6% to $306.7 million. The company finished the quarter with $283.6 million cash versus $283 million debt and continued buybacks, repurchasing about 7.9 million shares in the quarter. Management highlights upcoming adult-use legalization in Virginia, a conditional medical license in Texas, and federal rescheduling that may reduce tax burdens as potential drivers for future improvement. » Altro su finance.yahoo.com
Green Thumb Industries positioned for selective post-rescheduling M&A rather than megadeals
After Curaleaf's takeover bid for Aurora Cannabis, Green Thumb Industries is well capitalized and likely to pursue disciplined, smaller acquisitions or distressed state-level assets rather than large megamergers. Rescheduling cannabis to Schedule III would reduce tax burdens and increase sector deal activity, but Green Thumb's management favors cash-flow preservation, buybacks and strict return thresholds. The company can use its cash and stronger balance sheet to pick up valuable real estate, licenses or processing capacity in high-conviction markets. » Altro su finance.yahoo.com
Green Thumb exceeds revenue forecast for Q2 2026, margins under pressure
Green Thumb reported Q2 revenue of $307 million, beating the consensus estimate; normalized EBITDA was $84 million. Gross margin fell from 50% to 45% and same-store sales declined by about 1%. Management expects stagnant revenue in Q3 due to price pressure, but emphasizes cash-flow strength, share buybacks and long-term growth drivers. The stock rose modestly in after-hours trading, up 2.44% to $10.09. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giugno 2026 | |
|---|---|---|
| Ricavi | 268,72 Mln | 8,00% |
| Utile lordo | 120,81 Mln | 2,64% |
| Utile netto | 4,27 Mln | 881,05% |
| EBITDA | 57,09 Mln | 3,63% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,45 Mld € |
Numero di azioni | 218,99 Mln |
Massimo/minimo a 52 settimane | 8,96 € - 4,55 € |
| Dividendi | No |
Beta | 0,92 |
Rapporto P/E | 14,22 |
Rapporto PEG | 0,04 |
Rapporto P/B | 0,92 |
Rapporto P/S | 1,47 |
Profilo aziendale
Green Thumb Industries Inc. beschäftigt sich mit der Herstellung, dem Vertrieb und dem Verkauf verschiedener Cannabisprodukte für den medizinischen Gebrauch und den Gebrauch durch Erwachsene in den Vereinigten Staaten. Es bietet Cannabisblüten sowie verarbeitete und verpackte Produkte an, darunter Pre-Rolls, Konzentrate, Vapes, Tinkturen, Esswaren, topische Produkte und andere cannabisbezogene Produkte unter den Marken Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles und RHYTHM. Das Unternehmen vertreibt seine Produkte in erster Linie an Einzelhandelsgeschäfte von Dritten und verkauft fertige Produkte direkt an Verbraucher in seinen eigenen Einzelhandelsgeschäften. Am 11. April 2022 besaß und betrieb es 77 Einzelhandelsgeschäfte in den Vereinigten Staaten. Das Unternehmen wurde im Jahr 2014 gegründet und hat seinen Hauptsitz in Chicago, Illinois.
| Nome | Green Thumb Industries |
| CEO | Benjamin Kovler |
| Sede centrale | Chicago,
il Canada |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 14/06/2018 |
| Dipendenti | 5000 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Pnk | GTBIF |
Cnq | GTII.CN |
Frankfurt | R9U2.F |
Düsseldorf | R9U2.DU |
München | R9U2.MU |
Scopri gli asset
Gli azionisti di Green Thumb Industries investono anche nei seguenti asset